Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KINE-101
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kine Doses First Patient in Ph 1b/2a Study in Patients with CIDP
Details : KINE-101 is a novel nanopeptide and a disease modifier that controls both humoral immunity and cell-mediated immune responses by activating Treg cells. Its investigated for CIDP.
Brand Name : KINE-101
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 13, 2024
Lead Product(s) : KINE-101
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?